ACC

ACC 2022: Updated findings further highlight benefit of sotagliflozin treatment in patients with T2D and CKD, regardless of cardiovascular disease presence.

ACC 2022. SODIUM-HF secondary findings, however, showed improvement in NYHA HF class and in QOL in the dietary intervention group.

ACC 2022. Findings suggest that more attention to monitoring cognitive functioning after a myocardial infarction is needed.

ACC 2022. Study assessed hypertension-related TikTok videos and found that 42% addressed alternative medicine, more than twice the number that focused on medical treatments.

ACC 2022. Black and Hispanic persons were 41% less likely than white individuals to receive CPR after cardiac arrest in public and 26% less likely when the event occurred in their home.

ACC 2022. Can a couple of cups of coffee per day keep cardiovascular disease at bay? Findings from 3 new studies shed light.

ACC 2022. Approximately 5% of hospitalizations for acute MI in the state were found attributable to elevated levels of traffic noise.

ACC 2022. ACC late-breaking clinical trial sessions begin Sat, April 2, 2022. Our short slide shows highlight the studies of interest to primary care clinicians.

At ACC 2022 on Sunday, 4-2, look for studies on icosapent ethyl and alirocumab, landmark research on HFrEF, and a novel anticoagulant for atrial fibrillation.

At ACC 2022 on Sunday, 4-2, look for studies on icosapent ethyl and alirocumab, landmark research on HFrEF, and a novel anticoagulant for atrial fibrillation.